2020
Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer.
Yang D, Leapman M, Gross C, Yu J. Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer. Journal Of Clinical Oncology 2020, 38: e19308-e19308. DOI: 10.1200/jco.2020.38.15_suppl.e19308.Peer-Reviewed Original ResearchMetastatic prostate cancerSystemic therapy initiationTherapy initiationNGS test resultsNGS testingSystemic therapyMetastatic diagnosisNGS testsProstate cancerCommon systemic therapySystemic therapy selectionRetrospective observational studyNext-generation sequencing testDe-identified databaseMPC patientsTherapy startClinical outcomesMedian timeTherapy changesTreatment choiceObservational studyTherapy selectionGenomic classifierPatientsTherapy
2016
Change in a 17-gene genomic prostate score over time in men with low- and intermediate-risk prostate cancer managed with active surveillance.
Leapman M, Cowan J, Nguyen H, Cooperberg M, Carroll P. Change in a 17-gene genomic prostate score over time in men with low- and intermediate-risk prostate cancer managed with active surveillance. Journal Of Clinical Oncology 2016, 34: 124-124. DOI: 10.1200/jco.2016.34.2_suppl.124.Peer-Reviewed Original ResearchGenomic Prostate ScoreAdverse pathological findingsActive surveillanceProstate cancerRadical prostatectomyPathological findingsFavorable-risk prostate cancerIntermediate-risk prostate cancerIntermediate clinical riskNCCN risk classificationSerial prostate biopsyRisk prostate cancerSubsequent clinical outcomesTime of surgeryRT-PCR assaysPT3a diseaseDefinitive therapyIntermediate riskOncologic outcomesClinical outcomesAdverse pathologySerial biopsiesProstate biopsyMedian changeSerial changes